(Alliance News) - Scancell Holdings PLC on Monday said it has signed a collaboration and non-exclusive research agreement with an undisclosed US-based clinical stage antibody company.
The company, which develops novel immunotherapies for the treatment of cancer, said this agreement covers monoclonal antibodies targeting tumour-associated glycans.
Tumour-associated glycans are glycan motifs that are associated with tumour malignancies and can be targeted by antibodies
Under the terms of the collaboration & research agreement, the unnamed Scancell's partner will conduct preclinical studies to evaluate Scancell's anti-tumour-associated glycans monoclonal antibodies for the treatment of cancer.
AIM-listed Scancell noted that this is the third collaboration agreement evaluating its pipeline of anti-tumour-associated glycans monoclonal antibodies that have been engineered using AvidiMab technology.
"This continued momentum with AvidiMab and our tumour-associated glycan antibodies demonstrates the growing excitement around this platform. This is another important collaboration for Scancell and illustrates the future value that this third platform could potentially generate for the company," said Scancell Chief Executive Cliff Holloway.
Scancell shares were trading 20% higher in London on Monday at 7.50 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)